By investigating its expression among The Cancer Genome Atlas (TCGA) tumor samples, we identify new evidence for the prognostic significance of FCRL6 in melanoma, breast, and lung cancer that collectively indicate its potential as a biomarker and therapeutic target. This evidence concerns the gene FCRL6 and melanoma.